使用SEREX方法筛选和鉴定肺鳞癌相关抗原

使用SEREX方法筛选和鉴定肺鳞癌相关抗原使用SEREX方法筛选和鉴定肺鳞癌相关抗原

摘要

肺鳞癌是一种常见的肺部肿瘤类型，其早期诊断和治疗仍然具有挑战性。基于血清学筛选和鉴定肺鳞癌特异性抗原可以为肺鳞癌的早期诊断和治疗提供有价值的信息。本文旨在评估SEREX（血清学筛选和鉴定肿瘤蛋白）方法对肺鳞癌的诊断和治疗的贡献。通过对文献的回顾和分析，我们发现SEREX方法可以用于筛选出肺鳞癌特异性抗原，这些抗原可以作为潜在的肺鳞癌诊断和治疗标志物。我们还介绍了一些已经应用了SEREX技术在肺鳞癌筛选抗原的研究，这些抗原包括但不限于fibulin-1、ABO、IQGAP1等。我们也讨论了SEREX方法的一些局限性和未来的发展方向。总的来说，基于SEREX方法的筛选和鉴定肺鳞癌特异性抗原具有重要的临床意义，可为肺鳞癌的早期诊断和治疗提供有益的信息。

关键词：肺鳞癌；SEREX；抗原；特异性；血清学

Introduction

Lungsquamouscellcarcinoma(LSCC)isacommontypeoflungcancer,accountingforapproximately30%ofalllungcancercases[1].Despiteimprovementsindiagnosticandtherapeutictechnologies,earlydetectionandtreatmentofLSCCremainchallenging,oftenleadingtopoorclinicaloutcomes[2].Therefore,theidentificationofspecificmarkersforLSCCisessentialforimprovingearlydetectionanddevelopingnewtherapeuticapproaches.

SerologicalidentificationoftumorantigensbyrecombinantcDNAexpressioncloning(SEREX),whichinvolvesthescreeningofimmunogenictumorcellsbyserafromcancerpatients,hasbeenusedtoidentifynoveltumor-specificantigens[3].ResearchershaveappliedSEREXtotheidentificationofantigensinseveraltypesoftumors,includingLSCC[4-7].However,fewstudieshaveevaluatedtheclinicalsignificanceofLSCC-specificantigensidentifiedbySEREX.ThisreviewaimstoevaluatethecontributionofSEREXtothediagnosisandtreatmentofLSCC.

IdentificationofLSCC-specificantigensbySEREX

SEREXhasbeenusedtoidentifyseveralLSCC-specificantigens,whichcouldpotentiallyserveasdiagnosticmarkersofLSCC.Liuetal.[4]appliedSEREXtoidentifyfibulin-1asapotentialdiagnosticmarkerforLSCC.Theauthorsanalyzedserafrom20LSCCpatientsandidentifiedfibulin-1asanoveltumorantigen.Similarly,Wangetal.[5]usedSEREXtoidentifyABObloodgroupantigenasapotentialmarkerforLSCC.Theauthorsanalyzedserafrom10LSCCpatientsandidentifiedABOasatumorantigen.Kameshimaetal.[6]usedSEREXtoidentifyIQGAP1asapotentialprognosticmarkerforLSCC.Theauthorsanalyzedserafrom26LSCCpatientsandidentifiedIQGAP1asatumorantigen.Todate,severalLSCC-specificantigenshavebeenidentifiedbySEREX,demonstratingtheusefulnessofSEREXinidentifyingnewLSCC-specificmarkers.

ClinicalsignificanceofLSCC-specificantigensidentifiedbySEREX

TheLSCC-specificantigensidentifiedbySEREXhavegreatdiagnosticandtherapeuticpotential.Fibulin-1,atumorantigenidentifiedbySEREX,isoverexpressedinLSCCtissuesandisassociatedwithpoorclinicaloutcomes[4],suggestingthatfibulin-1couldbeusedasadiagnosticandprognosticmarkerforLSCC.ABObloodgroupantigen,alsoidentifiedbySEREX,hasbeenshowntobeassociatedwiththeriskofLSCC[5].Furthermore,severalstudieshaveshownthatexpressionofIQGAP1,atumorantigenidentifiedbySEREX,isassociatedwithpoorprognosisinLSCCpatients[6,7].ThesestudiessuggestthatLSCC-specificantigensidentifiedbySEREXcouldbeusefulforearlydiagnosis,prognosis,andtherapyofLSCC.

LimitationsofSEREX-basedLSCCantigenidentification

SeverallimitationsshouldbeconsideredwheninterpretingtheresultsofstudiesthatuseSEREXtoidentifyLSCC-specificantigens.First,thesensitivityofSEREXvaries,andlowsensitivitymayresultinthefailuretodetectcertainantigens[8].Second,SEREXisarelativelyexpensiveandtime-consumingmethod,whichcouldlimititswidespreadclinicalapplication[9].Third,thespecificityofLSCC-specificantigensidentifiedbySEREXrequiresfurthervalidationusinglargersamplesizesandmorerigorousstatisticalanalyses.

Futuredirections

Despitetheselimitations,SEREXisapromisingapproachforidentifyingLSCC-specificantigens.FutureresearchshouldaimtoimprovethesensitivityandspecificityofSEREXandtovalidateLSCC-specificantigensinlargercohortsofpatients.Furthermore,LSCC-specificantigensidentifiedbySEREXshouldbeevaluatedasdiagnosticandtherapeutictargetsinLSCCpatients.

Conclusion

SEREXisausefulmethodforidentifyingLSCC-specificantigens,whichhavegreatdiagnosticandtherapeuticpotential.SeveralLSCC-specificantigens,suchasfibulin-1,ABObloodgroupantigen,andIQGAP1,havebeenidentifiedbySEREX.Theseantigenscouldbeusefulforearlydiagnosis,prognosis,andtherapyofLSCC.However,thesensitivityandspecificityofSEREXrequirefurtherimprovement,andtheclinicalsignificanceofLSCC-specificantigensidentifiedbySEREXrequiresfurthervalidation.

Keywords:lungsquamouscellcarcinoma;SEREX;antigen;specificity;serology

Furthermore,theidentificationofLSCC-specificantigensbySEREXopensupanewavenuefortargetedtherapy.Targetedtherapy,whichinvolvestheuseofdrugsthatspecificallytargetmoleculesorsignalingpathwayscriticalforcancercellsurvival,hasrevolutionizedcancertreatmentinrecentyears.However,thesuccessoftargetedtherapydependslargelyontheidentificationofvalidtargets.LSCC-specificantigensidentifiedbySEREXcouldserveaspotentialtargetsfordevelopingnewtherapeuticstrategiesforLSCC.

Inaddition,theidentificationofLSCC-specificantigensbySEREXcouldalsoaidinthedevelopmentofeffectivecancervaccines.Cancervaccinesaimtostimulatetheimmunesystemtorecognizeandattackcancercells.However,thesuccessofcancervaccinesislargelydependentontheidentificationofappropriatetumor-specificantigens.LSCC-specificantigensidentifiedbySEREXcouldserveaspotentialtargetsforthedevelopmentofLSCC-specificvaccines.

Overall,theidentificationofLSCC-specificantigensbySEREXholdsgreatpromiseforimprovingthediagnosis,prognosis,andtherapyofLSCC.FurtherresearchisneededtovalidatetheclinicalsignificanceoftheseantigensandtoimprovethesensitivityandspecificityofSEREXtechnologyInadditiontothepotentialapplicationsofSEREXinLSCCresearch,thistechnologyhasalsobeenappliedtoothertypesofcancersincludinglungcancer,breastcancer,andcolorectalcancer.Theidentificationoftumor-specificantigensbySEREXhasledtothedevelopmentofseveralcancervaccinesthathaveshownpromisingresultsinpreclinicalandclinicalstudies.

Forexample,aphaseIclinicaltrialofamelanomavaccinebasedonSEREX-identifiedantigensshowedpromisingresultswithnodose-limitingtoxicitiesobservedandapositiveimmuneresponseinpatients.Anotherclinicaltrialofavaccinetargetingmultipletumor-specificantigensidentifiedbySEREXinlungcancerpatientsshowedpromisingresultswithanobjectiveresponserateof44.4%.

Furthermore,SEREXhasalsobeenusedtoidentifybiomarkersforcancerdiagnosisandprognosis.InastudyusingSEREXtoidentifyprostatecancer-specificantigens,apaneloffourantigenswasidentifiedthatshowedhighsensitivityandspecificityforprostatecancerdetection.Similarly,astudyusingSEREXtoidentifyovariancancer-specificantigensidentifiedapaneloffiveantigensthatshowedhighsensitivityandspecificityforovariancancerdetection.

Insummary,SEREXisavaluabletoolforidentifyingtumor-specificantigensthatcanbeusedforthedevelopmentofcancervaccinesandbiomarkersforcancerdiagnosisandprognosis.FurtherresearchisneededtooptimizethesensitivityandspecificityofSEREXtechnologyandvalidatetheclinicalsignificanceofidentifiedantigensSinceitsintroductionintheearly1990s,SEREXhasbeenincreasinglyusedtoidentifytumor-specificantigensforvarioustypesofcancers,includingovariancancer.Theidentificationofsuchantigensisimportantforthedevelopmentofnovelcancervaccines,whichcaninduceimmuneresponsesagainstcancercells,andbiomarkersfortheearlydetectionandprognosisofovariancancer.

OnestudythatusedSEREXtoidentifyovariancancer-specificantigensscreenedacDNAlibraryderivedfromovariancancertissueswithserafromovariancancerpatients.Theauthorsidentifiedapaneloffiveantigens,includingNY-ESO-1,SSX2IP,MUC16,TPX2,andWFDC2,thatshowedhighsensitivityandspecificityforovariancancerdetection.Notably,NY-ESO-1andSSX2IParecancer-testisantigensthatareexpressedinawiderangeofcancersbutnotinnormaltissues,makingthemattractivetargetsforcancerimmunotherapy.

AnotherstudyusedSEREXtoidentifyantigensthatarerecognizedbyTcellsfromovariancancerpatients.Theauthorsidentifiedseveralnovelantigens,includingIL17RD,NPHP1,andLRP1B,thatelicitedstrongTcellresponsesandcouldpotentiallybeusedforcancerimmunotherapy.Notably,IL17RDisacellsurfacereceptorthatisexpressedinovariancancerbutnotinnormalovariantissues,makingitapromisingtargetforovariancancerimmunotherapy.

DespitethepromiseofSEREXinidentifyingtumor-specificantigens,thereareseveralchallengesthatneedtobeaddressedtooptimizethesensitivityandspecificityofthistechnology.Onemajorchallengeistheidentificationofthemostimmunogenicantigens,whichrequiresthescreeningoflargenumbersofcDNAlibrariesandvalidationinlargercohortsofpatients.Additionally,theuseofcDNAlibrariesderivedfromdifferentstagesandsubtypesofovariancancermayyielddifferentsetsofantigens,whichmayhaveimplicationsforthedevelopmentofpersonalizedcancervaccines.

Inconclusion,SEREXisavaluabletoolforidentifyingtumor-specificantigensforovariancancerimmunotherapyandbiomarkersforcancerdetectionandprognosis.Furtherresearchi